Skip to main content
Caplight Logo









Trioar

Trioar

Private
DaejeonEnterprise Softwarehttps://trioar.co.kr/

Last Round

Grant

Jul 6, 2026

Est. Valuation

$56.9M

Total Funding Raised

$53.16M

Company Overview

Trioar is a biotechnology company that develops next-generation antibody-based therapeutics, including antibody-drug conjugates (ADCs) and immuno-oncology treatments, using its proprietary TROCAD™ and TROSIG™ platform technologies.

Sector

Enterprise Software

Verticals

AR/VR Experiences, Marketing, Event Management, Content Creation

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Non-AI

Keywords

augmented realityARAR developmentinteractive contentweb ARmobile ARAR marketingAR platformimmersive experienceAR filtersAR exhibition3D contentspatial computingdigital engagement

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Trioar Comparables

Compare Trioar with similar companies based on industry and business-model similarity.

Trioar comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Seerslab
77%
Zappar
71%
Blippar
71%

Trioar Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 6, 2026
Series BAug 28, 2025
Series BJul 17, 2025
Series AMay 23, 2023
Pre SeedFeb 24, 2022
Angel
May 1, 2021

Trioar Investors

Notable investors and investment history

Trioar investors
InvestorRounds
CKD Venture CapitalSeries B
Shinhan Venture InvestmentSeries B
KB InvestmentSeries B, Pre Seed, Series A
Woori Venture Partners Co., Ltd.Series B
Kiwoom InvestmentSeries B, Series A
Hyundai Technology InvestmentSeries B
Jin & Investment PartnersSeries B

Trioar Filings

Explore SEC and related filing metadata, where available.

Trioar filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Trioar's valuation, stock price, and market status.

Is Trioar a public or private company?

Trioar is a private company.

What is the current stock price of Trioar?

Trioar is a private company with no public stock price. No recent secondary market data is available.

How much is Trioar worth (valuation)?

Valuation information for Trioar is not publicly available.

Can I buy Trioar stock?

Trioar shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Trioar's last funding round?

Trioar's most recent funding round was Series B on August 28, 2025.

Who are the main investors in Trioar?

Key investors in Trioar include LSK Investment, LSK Investment, Woori Venture Partners.

Will Trioar IPO soon?

No public IPO plans have been announced for Trioar.

How can I track Trioar secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Trioar's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDaejeon
Year Founded2021
Last FundingJul 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?